CY 2023 ASX Announcements
September
21/09/2023 Financial improvements continue
August
29/08/2023 EX1 – Annual Report
29/08/2023 EX1 – FY2023 Appendix 4E
29/08/2023 EX1 – Appendix 4G and Corporate Governance Statement for FY2023
July
28/07/2023 Quarterly Activities Report and Appendix 4C
June
22/06/2023 EX1 – Initial Director’s Interest Notice – MD
22/06/2023 EX1 – Change of Director’s Interest Notice – CB
22/06/2023 EX1 – Final Director’s Interest Notice – JW
22/06/2023 Update and Changes to the Board
May
18/05/2023 Change in substantial holding – ID
18/05/2023 Application for quotation of securities – EX1
12/05/2023 Application for quotation of securities – EX1
12/05/2023 Notification regarding unquoted securities – EX1
01/05/2023 Update – Proposed issue of securities – EX1
April
28/04/2023 Change in substantial holding – ID
28/04/2023 Change of Director’s Interest Notice – JW
28/04/2023 Results of Meeting
28/04/2023 Application for quotation of securities – EX1
28/04/2023 EX1 early stage success with in house Elastin (ELN) program
27/04/2023 Quarterly Activities Report and Appendix 4C
26/04/2023 Results of Non-Renounceable Rights Issue
05/04/2023 Rights Issue Prospectus and Extension of Closing Date
05/04/2023 Update – Proposed issue of securities – EX1
March
31/03/2023 Despatch of Non-Renounceable ProRata Rights Issue Prospectus
29/03/2023 Notice of General Meeting/Proxy Form
23/03/2023 Proposed issue of securities – EX1
23/03/2023 Proposed issue of securities – EX1
23/03/2023 Exopharm Limited announces Non-Renounceable Pro Rata Rights
23/03/2023 Notice to Ineligible Shareholder
23/03/2023 Disclosure Document – Rights Issue Prospectus
09/03/2023 Notification regarding unquoted securities – EX1
09/03/2023 Notice under s708A(12C)(e) of the Corporations Act 2001(Cth)
09/03/2023 EX1 to Receive $1m from the Issue of Convertible Notes
09/03/2023 Trading Halt
09/03/2023 EX1 to Receive $0.431m in Prepayment of R&D Tax Incentive
February
27/02/2023 Appendix 4D and Half Year Report for period 31 December 2022
22/02/2023 Initial Director’s Interest Notice – CB
22/02/2023 Final Director’s Interest Notice – JK
22/02/2023 Board changes adds Australian capital markets expertise
15/02/2023 Ceasing to be a substantial holder
13/02/2023 Added Funding for 2023
09/02/2023 Trading Halt
January
31/01/2023 Quarterly Activities Report and Appendix 4C
CY 2022 ASX Announcements
December
20/10/2022 Notification of cessation of securities – EX1
20/10/2022 Final Director’s Interest Notice
20/10/2022 Operations review, Board and other changes
November
25/11/2022 EX1 to Receive $0.96m in Prepayment of R&D Tax Incentive
24/11/2022 Constitution
24/11/2022 Results of Meeting
17/11/2022 Exosome manufacture taken to the next level
14/11/2022 EX1 will commence LEAP technology transfer to AIRM under MSA
08/11/2022 Upcoming Conference Presentation ANZSEV2022
October
31/10/2022 Quarterly Activities Report and Appendix 4C
27/10/2022 Upcoming Webinar
27/10/2022 Exopharm Received R&D Tax Incentive Refund
25/10/2022 2022 AGM Notice of Meeting and Proxy
25/10/2022 2022 AGM Letter to Shareholders and Proxy
24/10/2022 Change in substantial holding
20/10/2022 Upcoming Webinar
14/10/2022 Notification regarding unquoted securities – EX1
13/10/2022 Upcoming Webinar
12/10/2022 EX1 Building Momentum with in-house Products
07/10/2022 Investor Presentation
September
28/09/2022 Study results indicate exosomes safe for clinical pursuit
09/09/2022 Date of Annual General Meeting 2022
August
31/08/2022 FY2022 Appendix 4E and Annual Report
31/08/2022 Appendix 4G and Corporate Governance Statement
July
Quarterly Activities Report and Appendix 4C
EX1 to receive a further $0.48m in prepaid R&D Tax Incentive
June
May
30/05/2022 Business Update
April
29/04/2022 Exopharm Ltd – March 2022 Quarterly Activities Report and Appendix 4C
CY 2021 ASX Announcements
November
16/11/2021 Exopharm to Present at Key Exosome Industry Event
October
27/10/2021 Quarterly Activities Report and Appendix 4C
26/10/2021 2021 AGM Notice of Meeting and Proxy
26/10/2021 2021 AGM Letter to Shareholders and Proxy
September
30/09/2021 Appointment of Company Secretary
27/09/2021 Exopharm LEAP Technology – Further Step Towards US Patent
08/09/2021 Exopharm LEAP Technology – Second Commercial Collaboration
03/09/2021 Change of Director’s Interest Notice – EM
01/09/2021 Change of Director’s Interest Notice – JW
01/09/2021 Change of Director’s Interest Notice – ID
01/09/2021 Cleansing Notice
01/09/2021 Application for quotation of securities – EX1
01/09/2021 Date of Annual General Meeting
01/09/2021 Initial Director’s Interest Notice – JK
August
31/08/2021 Dr Jenn King joins Exopharm Board
30/08/2021 Appendix 4G and Corporate Governance Statement
30/08/2021 FY2021 Appendix 4E and Annual Report
26/08/2021 Science Webinar – Overcoming the Nucleic Acid Delivery Challenge
20/08/2021 Investor Webinar Presentation
02/08/2021 Notification regarding unquoted securities
July
27/07/2021 Quarterly Activities Report and Appendix 4C
02/07/2021 Partnering & Licensing Focus Continues
June
30/06/2021 Investor Presentation
03/06/2021 Exopharm LEAP Exosome Technology Granted 1st National Patent
May
06/05/2021 Appendix 2A
April
30/04/2021 Change in substantial holding – ID
30/04/2021 Cleansing Notice
30/04/2021 Appendix 2A
20/04/2021 Proposed issue of Securities – EX1
20/04/2021 Exopharm Receives Firm Commitments to Raise $12 million
16/04/2021 Investor Presentation – Delivering Transformative Medicines
16/04/2021 Quarterly Activities Report and Appendix 4
15/04/2021 Trading Halt
08/04/2021 Exopharm Shareholder Update – Revenue Focus in 2021
08/04/2021 Appendix 3G
06/04/2021 LEAP Technology- Advanced EV Medicines from Blood Components
06/04/2021 Positive PLEXOVAL II Phase 1 Clinical Trial Results
01/04/2021 Securities Trading Policy
01/04/2021 Preclinical Data from Osteoarthritis Animal Study
February
26/02/2021 Appendix 4D and Half Year Financial Report
26/02/2021 Securities Trading Policy
16/02/2021 Exopharm presents at Bio CEO & Investor Digital Conference
10/02/2021 Change of Director’s Interest Notices – JW and ID
09/02/2021 Substantial Shareholder notices – amendment
08/02/2021 Response to ASX Price and Volume Query
January
29/01/2021 Exopharm Quarterly Activities Report and Appendix 4C
21/01/2021 Progress Points To Partnering Readiness
05/01/2021 Initial Director’s Interest Notice – EM
05/01/2021 Final Director’s Interest Notice – DP
05/01/2021 Exopharm Board Changes
04/01/2021 Change in substantial holding
04/01/2021 Becoming a substantial holder
04/01/2021 Lapse of Performance Rights
CY 2020 ASX Announcements
December
30/12/2020 Response to ASX Price and Volume Query
23/12/2020 Change of Director’s Interest Notice
22/12/2020 Shareholder Update
18/12/2020 Appendix 2A
11/12/2020 Release of Securities from 24 Month Escrow
02/12/2020 Change of Director’s Interest Notice
02/12/2020 Cleansing Notice
02/12/2020 Appendix 2A
November
30/11/2020 Results of Meeting
13/11/2020 Change of Registered Office Address
11/11/2020 Exopharm to Present at Key Exosome Industry Event
09/11/2020 Appendix 2A, Appendix 3G and Cleansing Notice
October
29/10/2020 Letter to Shareholders – Annual General Meeting
29/10/2020 Notice of Annual General Meeting/Proxy Form
29/10/2020 Results of Extraordinary General Meeting
27/10/2020 September Quarterly Report and Appendix 4C
22/10/2020 Plexoval II First Dosing and $2.1m R&D Rebate Received
06/10/2020 Annual General Meeting Date and Director Nominations
September
24/09/2020 Letter to Shareholders
24/09/2020 Notice of Extraordinary General Meeting/Proxy Form
18/09/2020 Shareholder Update: Investor Deck
17/09/2020 Change in Substantial Holding
15/09/2020 Proposed Issue of Securities
15/09/2020 Appointment of Manufacturing Expert & Corporate Advisor
14/09/2020 Annual Report
09/09/2020 Cleansing Notice
08/09/2020 Appendix 2A
August
27/08/2020 Proposed Issue of Securities
27/08/2020 Proposed Issue of Securities
27/08/2020 Exopharm Raises $10M in Well-supported Placement
26/08/2020 Appendix 4G and Corporate Governance Statement FY 2020
26/08/2020 Appendix 4E – Preliminary Final Report for Year Ended 30 June 2020
21/08/2020 Trading Halt Announcement
21/08/2020 Investor Presentation
19/08/2020 Shareholder Update
July
30/07/2020 June 2020 Quarterly Activities Report and Appendix 4C
22/07/2020 Shareholder Update
21/07/2020 Monsoon Communications Morning Twilight Briefing Webinar
June
16/06/2020 Company Secretary and services update
12/06/2020 Top 20 Shareholders Report
12/06/2020 Additional IP empowers Exopharm’s engineered exosome pipeline
May
28/05/2020 Shareholder Update and Webinar
25/05/2020 Plexaris product engineered to deliver anti-cancer drug
April
24/04/2020 March 2020 Appendix 4C and Quarterly Report
01/04/2020 Plexoval Update
March
26/03/2020 Shareholder Update
05/03/2020 Investor Deck
February
24/02/2020 Statement clarification
20/02/2020 APPENDIX 4D – Interim Financial Report for the half year to 31 December 2019
20/02/2020 Cevaris testing shows positive results in bladder control model
19/02/2020 Cevaris testing shows positive results in models of erectile dysfunction
14/02/2020 Media Release: Erectile Dysfunction a Potential Target for Exopharm’s Exosomes
12/02/2020 Independent Plexaris and Cevaris testing shows positive and unique results
10/02/2020 Shareholder Update. Exopharm in 2020. News, Deals and Clinical Trials
05/02/2020 Investor Deck
January
29/01/2020 December 2019 Quarterly Activities Report and Appendix 4C
28/01/2020 Plexoval Update – World First Human Clinical Trials
CY 2019 ASX Announcements
November
25/11/2019 Key Management Contracts
18/11/2019 Results of AGM Meeting 2019
14/11/2019 Development Program Update
01/11/2019 Investor Deck, November 2019
October
28/10/2019 Appointment of Chief Commercial Officer
25 /10/2019 Shareholder Newsletter – October
25/10/2019 Quarterly 4c
17/10/2019 Notice of Annual General Meeting
17/10/2019 Annual Report
16/10/2019 Notice of Change of Interests of Substantial Holder
September
16-09-2019 Change of Director’s Interest Notice – Appendix 3Y
16/09/2019 Issue of Shares and Appendix 3B
09/09/2019 Results of General Meeting
August
30/08/2019 Appendix 4E and Annual Financial Report FY 2019
30/08/2019 Appendix 4G and Corporate Governance Statement FY 2019
26/08/2019 Plexoval Exosome Wound Healing Human Study Starts
19/08/2019 Appendix 3Y. Change of Director’s Interest Notice
19/08/2019 Appendix 3B. New Issue Announcement
16/08/2019 Closure of Offer Under the Share Purchase Plan
13/08/2019 Application for Quotation of Additional Securities and Agreement
08/08/2019 Notice of General Meeting
01/08/2019 Issue of Placement Shares
July
29/07/2019 EX1 ASX Announcement – Upcoming Release of Shares from Escrow
25/07/2019 Share Purchase Plan (SPP) Offer Document
25/07/2019 Cleansing Statement – Notice under ASIC Class Order [CO 09/425]
25/07/2019 Exopharm Appendix 4C – June Quarter
24/07/2019 Investor Deck Placement and Share Purchase Plan
24/07/2019 Share Placement and Share Purchase Plan Announcement
22/07/2019 Exopharm Secures Ethics Approval for the Plexoval Clinical Trial
22/07/2019 Trading Halt
19/07/2019 Appendix 3B New Issue Announcement
05/07/2019 Escrow Release
May
23/05/2019 Upcoming Release of Shares from Escrow
22/05/2019 Acceleration of Development Activities
April
30/04/2019 March 2019 Quarterly Activities Report and Appendix 4C
09/04/2019 Investor Presentation
01/04/2019 April 2019 Market Update
March
27/03/2019 Explainer: The critical bottleneck of exosome isolation and the power of Exopharm’s LEAP technology
February
21/02/2019 Dec 2018 Half-Yearly Report and Appendix 4D
05/02/2019 Positive outcomes from initial animal studies of Plexaris and Exomeres
January
31/01/2019 January 2019 Quarterly Cash Flow Report
31/01/2019 December 2018 Quarterly Activities Report
CY 2018 ASX Announcements
December
28/12/2018 Investor Deck
28/12/2018 Notice of Initial Substantial Holder
18/12/2018 Initial Director Interests x 3
18/12/2018 Closes Initial Public Offering Fully Subscribed and Lists on the ASX
14/12/2018 Capital Structure and Restricted Securities
14/12/2018 Securities Trading Policy
14/12/2018 Updated Pro-Forma and Commitments
14/12/2018 Financial Statements – Year Ended 30 June 2018
14/12/2018 Financial Statements – Year Ended 30 June 2017
14/12/2018 Financial Statements – Year Ended 30 June 2016
14/12/2018 Constitution
14/12/2018 Prospectus
14/12/2018 Appendix 1A and Information Form and Checklist
14/12/2018 Top 20 Holders
14/12/2018 Distribution Schedule
14/12/2018 ASX Notice – Admission to the Official List
Join the Exopharm Mailing List
Join the Exoparm mailing List and receive occasional updates and important information about our work.
